Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ANALOGIC CORP
Report date October 31, 2016 · Filed November 02, 2016
Section 16 reporting ended · disclosed 2016-11-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,837 |
Ending reported balance
After 2016-10-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-31 · Exercise / conversion · Acquired 2,469 · Balance 27,000 F1: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. Row 2 · 2016-10-31 · Tax withholding · Disposed 1,163 · Balance 25,837 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,949 |
Reported balance
After 2016-10-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-31 · Exercise / conversion · Disposed 2,469 · Balance 4,949 F1: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2016-10-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2016-10-31 · Disposition to issuer · Disposed 4,939 · Balance 0 F1: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,246 |
Reported balance
After 2016-10-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2016-10-31 · Disposition to issuer · Disposed 3,749 · Balance 11,246 F2: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,449 |
Reported balance
After 2016-10-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2016-10-31 · Disposition to issuer · Disposed 7,628 · Balance 5,449 F3: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 F2: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,217 |
Reported balance
After 2016-10-31 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2016-10-31 · Disposition to issuer · Disposed 13,390 · Balance 1,217 F4: Represents forfeiture of performance based RSU's granted on 9/15/16 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2019. F3: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016.
F2: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017.
F3: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018
F4: Represents forfeiture of performance based RSU's granted on 9/15/16 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2019.
HARVARD BIOSCIENCE INC
Report date August 15, 2025 · Filed August 19, 2025
Section 16 reporting ended · disclosed 2025-08-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,796,040 |
Reported balance
After 2025-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-08-15 · Disposition to issuer · Disposed 49,048 · Balance 2,796,040 F1: Represents forfeiture of time-based restricted stock units ("RSUs") granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 2,762,840 |
Reported balance
After 2025-08-15 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-08-15 · Tax withholding · Disposed 33,200 · Balance 2,762,840 F2: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,643,508 |
Reported balance
After 2025-08-15 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2025-08-15 · Disposition to issuer · Disposed 119,332 · Balance 2,643,508 F3: Represents forfeiture of time-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 2,631,968 |
Reported balance
After 2025-08-15 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2025-08-15 · Tax withholding · Disposed 11,540 · Balance 2,631,968 F4: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 2,565,905 |
Reported balance
After 2025-08-15 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2025-08-15 · Disposition to issuer · Disposed 66,036 · Balance 2,565,905 F5: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 2,452,566 |
Reported balance
After 2025-08-15 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2025-08-15 · Disposition to issuer · Disposed 113,366 · Balance 2,452,566 F6: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer. F7: This total includes 375,005 RSUs with performance based vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents forfeiture of time-based restricted stock units ("RSUs") granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.
F2: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.
F3: Represents forfeiture of time-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.
F4: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with an RSU award previously granted to the Reporting Person that vested on August 15, 2025.
F5: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 6, 2023 in connection with the Reporting Person resigning from all services with the Issuer.
F6: Represents forfeiture of performance-based RSUs granted to the Reporting Person on March 5, 2024 in connection with the Reporting Person resigning from all services with the Issuer.
F7: This total includes 375,005 RSUs with performance based vesting conditions.
OSI SYSTEMS INC
Report date July 05, 2019 · Filed July 08, 2019
Section 16 reporting ended · disclosed 2019-07-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,831 |
Reported balance
After 2019-07-05 transaction · row 1
1 source rowRow 1 · 2019-07-05 · Tax withholding · Disposed 233 · Balance 3,831 F1: Pursuant with a net settlement, shares of stock were tendered to satisfy tax withholding obligations. No shares of stock were sold. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant with a net settlement, shares of stock were tendered to satisfy tax withholding obligations. No shares of stock were sold.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2021 Filed May 25, 2021 20:26 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 24,312 | $2.63 | $63,940.56 |
DisclosureSEC source: 0000921895-21-001485 · form412799001_05252021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 670,358 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 14,876 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · derivative · entry 6 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,002 Underlying: Common Stock · 14,876 shares Expires 2027-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 14,876 | $7.03 | $104,578.28 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · nonDerivative · entry 4 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,778 F5 · price: This transaction was executed in multiple trades at prices ranging from $7.02 to $7.05, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F6 · balance_after: Includes (a) the shares and awards described in footnote (4) above, less (b) the disposition of shares reported in footnote (5) above. Read SEC document |
| May 20, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 14,876 | $2.63 | $39,123.88 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · nonDerivative · entry 3 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,294,654 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · balance_after: Includes (a) the shares and awards described in footnote (3) above, plus (b) the acquisition of 14,876 shares of common stock pursuant to the exercise of stock options as reported on this Form 4. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 39,188 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · derivative · entry 5 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,878 Underlying: Common Stock · 39,188 shares Expires 2027-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 39,188 | $7.17 | $280,977.96 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,778 F2 · price: This transaction was executed in multiple trades at prices ranging from $7.07 to $7.26, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes (a) the shares and awards described in footnote (1) above, less (b) the disposition of shares reported in footnote (2) above. Read SEC document |
| May 19, 2021 Filed May 21, 2021 20:19 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 39,188 | $2.63 | $103,064.44 |
DisclosureSEC source: 0000921895-21-001455 · form412799001_05212021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,318,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 685,234 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:22 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionStock option (right to buy) · Derivative | 39,188 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0000921895-21-001420 · form412799001_05192021.xml · derivative · entry 3 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,066 Underlying: Common Stock · 39,188 shares Expires 2027-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:22 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 39,188 | $7.41 | $290,383.08 |
DisclosureSEC source: 0000921895-21-001420 · form412799001_05192021.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,788 F2 · price: This transaction was executed in multiple trades at prices ranging from $7.34 to $7.52, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes (a) the shares and awards described in footnote (1) above, less (b) the disposition of shares reported in footnote (2) above. Read SEC document |
| May 18, 2021 Filed May 19, 2021 21:22 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Exercise / conversionCommon Stock | 39,188 | $2.63 | $103,064.44 |
DisclosureSEC source: 0000921895-21-001420 · form412799001_05192021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,318,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 685,234 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 22:51 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | SaleCommon Stock | 35,000 | $5.98 | $209,300.00 |
DisclosureSEC source: 0000921895-21-000761 · form412799001_03162021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279,778 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.98 to $6.07, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 823,176 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 646,046 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:31 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 186,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000618 · form412799gre_03032021.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,314,778 F3 · shares: Represents an award of 186,674 restricted stock units with performance based vesting conditions. These restricted stock units will vest upon the achievement of a relative total shareholder return of the Issuer's common stock during the period from March 1, 2021 to the earlier of (i) December 31, 2023, and (ii) the date of a change of control (the "Measurement Period"), measured relative to the Russell 2000 index and based on the 20-day trading average beginning on the first day of the Measurement Period and ending on the last day of the Measurement Period, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:31 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 194,698 | $0.00 | $0.00 |
DisclosureSEC source: 0000921895-21-000618 · form412799gre_03032021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,128,104 F1 · shares: Represents an award of 194,698 restricted stock units that will vest in three equal installments on December 31, 2021, 2022 and 2023, subject to the terms set forth in an award agreement between the Issuer and the Reporting Person. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023, (c) 243,072 restricted stock units that will fully vest on July 8, 2021, (d) 209,180 remaining restricted stock units that will vest on January 1, 2022 and 2023, (e) 636,502 restricted stock units with performance based vesting conditions tied to relative total shareholder return, and (f) 681,046 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 22:35 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 30,478 | $4.29 | $130,750.62 |
DisclosureSEC source: 0000921895-21-000028 · form412799gre_01052021.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,933,406 F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person which vested in part on January 1, 2021. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 22:35 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 26,231 | $4.29 | $112,530.99 |
DisclosureSEC source: 0000921895-21-000028 · form412799gre_01052021.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,963,884 F1 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with a restricted stock unit award previously granted to the Reporting Person which vested in part on December 31, 2020. F2 · balance_after: Includes (a) 163,606 remaining restricted stock units that will vest on December 31, 2021, 2022 and 2023; (b) 243,072 restricted stock units that will fully vest on July 8, 2021; (c) 209,180 restricted stock units that will vest on January 1, 2022 and 2023; (d) 636,502 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (e) 711,524 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 157,490 | $3.49 | $549,640.10 |
DisclosureSEC source: 0001209191-20-042223 · doc4.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,990,115 F3 · shares: The shares were disposed of to satisfy the Reporting Person's tax withholding obligation in connection with restricted stock unit and performance restricted stock unit awards previously granted to the Reporting Person which vested in part on July 8, 2020. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, less (b) the disposition of shares reported in footnote (3) above. Read SEC document |
| July 08, 2020 Filed Jul 11, 2020 00:00 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 209,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042223 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,147,605 F1 · shares: On July 8, 2019, the Reporting Person was granted an award of 418,360 restricted stock units with performance based vesting conditions based on the achievement of a relative total shareholder return of the Issuer's common stock from July 8, 2019 to the earlier of (i) July 8, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index). The target number of the restricted stock units that may be earned was reported on the date of grant; the maximum amount is 150% of the number then reported. As a result of the Issuer's performance based on such performance targets, the reporting person earned 150% of the target amount, subject to continuation of employment through the remaining vesting dates. Accordingly, the reported transaction reflects the acquisition of 209,180 additional performance restricted stock units earned above the target grant. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 218,141 restricted stock units that will vest on December 31, 2020, 2021, 2022 and 2023; (c) 243,072 restricted stock units that will fully vest on July 8, 2021; (d) 313,770 restricted stock units that will vest in three equal installments on January 1, 2021, 2022 and 2023; (e) 636,502 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 526,940 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantStock option (right to buy) · Derivative | 470,254 | $0.00 Strike: $2.63 | $0.00 |
DisclosureSEC source: 0001209191-20-036759 · doc4.xml · derivative · entry 3 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,254 Underlying: Common Stock · 470,254 shares Expires 2027-06-11 F5 · derivative.exercise_date: The options vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 218,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036759 · doc4.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,938,424 F3 · shares: Represents an award of 218,141 restricted stock units with performance based vesting conditions. These restricted stock units will vest in equal installments on June 11, 2021, 2022 and 2023, and are linked to the achievement of a relative total shareholder return of the Issuer's common stock from June 11, 2020 to the earlier of (i) June 11, 2021 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index and based on the 20-day trading average price before each such date). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F4 · balance_after: Includes (a) the shares and awards described in footnote (2) above, and (b) the award described in footnote (3) above. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 22:52 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 218,141 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036759 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,720,284 F1 · shares: Represents an award of 218,141 restricted stock units that will vest in four equal installments on December 31, 2020, 2021, 2022 and 2023. F2 · balance_after: Includes (a) the award described in footnote (1) above, (b) 202,875 restricted stock units that will fully vest on July 8, 2020; (c) 243,072 restricted stock units that will fully vest on July 8, 2021; (d) 313,770 restricted stock units that will vest in three equal installments on January 1, 2021, 2022 and 2023; (e) 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 324,066 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| May 23, 2020 Filed May 27, 2020 20:30 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 10,302 | $2.66 | $27,403.32 |
DisclosureSEC source: 0001209191-20-032305 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502,143 F1 · balance_after: Includes (a) 202,875 restricted stock units that will fully vest on July 8, 2020; (b) 243,072 restricted stock units that will fully vest on July 8, 2021; (c) 313,770 restricted stock units that will vest in three equal installments on January 1, 2021, 2022 and 2023; (d) 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (e) 324,066 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| May 07, 2020 Filed May 8, 2020 20:49 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 10,000 | $2.53 | $25,300.00 |
DisclosureSEC source: 0001209191-20-027953 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,512,445 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.525 to $2.53, inclusive. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on May 23, 2020; (b) 202,875 restricted stock units that will fully vest on July 8, 2020; (c) 243,072 restricted stock units that will fully vest on July 8, 2021; (d) 313,770 restricted stock units that will vest in three equal installments on January 1, 2021, 2022 and 2023; (e) 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 299,268 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 21:42 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Tax withholdingCommon Stock | 32,959 | $3.05 | $100,524.95 |
DisclosureSEC source: 0001209191-20-001080 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,631 F1 · shares: The shares were disposed to satisfy the Reporting Person's tax withholding obligation in connection with deferred stock awards previously granted to the Reporting Person which vested in part on January 1, 2020. F2 · balance_after: Reflects the transfer of 71,631 shares from the James W. Green Revocable Trust to James W. Green, individually. This reflects only a change in the form of beneficial ownership of the Reporting Person without affecting the Reporting Person's pecuniary interest in such shares and is, therefore, being voluntarily reported herein. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:06 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 10,000 | $2.61 | $26,100.00 |
DisclosureSEC source: 0001209191-19-056321 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by James W. Green Revocable Trust Disclosed balance after: 1,535,404 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.60 to $2.62, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 217,637 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 11:38 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 10,000 | $2.49 | $24,850.00 |
DisclosureSEC source: 0001209191-19-046448 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by James W. Green Revocable Trust Disclosed balance after: 1,525,404 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.47 to $2.50, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 207,637 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 21:37 UTC Amendment | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 20,000 | $2.47 | $49,320.00 |
DisclosureSEC source: 0001209191-19-045567 · doc4a.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by James W. Green Revocable Trust Disclosed balance after: 1,515,404 F1 · kind: This amendment is being filed to correct the transaction code in the initial filing to clarify that this acquisition was an open-market purchase. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.43 to $2.49, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 197,637 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:05 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 20,000 | $2.47 | $49,320.00 |
DisclosureSEC source: 0001209191-19-045485 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by James W. Green Revocable Trust Disclosed balance after: 1,515,404 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.43 to $2.49, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020; (c) a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021; (d) a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023; (e) a deferred stock award of 418,360 restricted stock units with performance based vesting conditions tied to relative total shareholder return; and (f) 197,637 shares of common stock beneficially owned by the Reporting Person. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 418,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041546 · doc4.xml · nonDerivative · entry 5 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,493,404 F9 · shares: Represents a deferred stock award of 418,360 restricted stock units with performance based vesting conditions. These restricted stock units shall vest based on the achievement of a relative total shareholder return of the Issuer's common stock from July 8, 2019 to the earlier of (i) July 8, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported. F10 · balance_after: Includes the equity described in footnotes (2), (3), (5), (7) and (9). Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 418,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041546 · doc4.xml · nonDerivative · entry 4 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,075,044 F7 · shares: Represents a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023. F8 · balance_after: Includes the equity described in footnotes (2), (3), (5) and (7). Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 243,072 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041546 · doc4.xml · nonDerivative · entry 3 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 656,684 F5 · shares: Represents a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021. F6 · balance_after: Includes the equity described in footnotes (2), (3) and (5). Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 202,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041546 · doc4.xml · nonDerivative · entry 2 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 413,612 F3 · shares: Represents a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020. F4 · balance_after: Includes the equity described in footnotes (2) and (3). Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 20:16 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | Disposition to issuerCommon Stock | 5,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-041546 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,737 F1 · shares: The subject restricted stock units were granted to the Reporting Person on January 2, 2019 and were forfeited as a result of the Reporting Person transitioning to his role as President and Chief Executive of the Issuer as of July 8, 2019, and stepping down from his roles as member of the Governance Committee and member of the Compensation Committee. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; and (b) 175,637 shares of common stock held by the Reporting Person. Read SEC document |
| July 05, 2019 Filed Jul 8, 2019 21:41 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | Tax withholdingCommon Stock | 233 | $116.69 | $27,188.77 |
DisclosureSEC source: 0001104659-19-039590 · a4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Pres., Spacelabs Healthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,831 F1 · shares: Pursuant with a net settlement, shares of stock were tendered to satisfy tax withholding obligations. No shares of stock were sold. Read SEC document |
| May 23, 2019 Filed May 24, 2019 21:28 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 35,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-032796 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,012 F1 · shares: Represents a deferred stock award of 35,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020. F2 · balance_after: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (b) a deferred stock award of 15,825 restricted stock units which vest quarterly in equal installments on June 30, 2019, September 30, 2019 and December 31, 2019; and (c) 165,087 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:31 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 21,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-000981 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,287 F1 · shares: Represents a deferred stock award of 21,100 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in satisfaction of the annual retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2019. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 21,100 restricted stock units which vest quarterly in equal installments on March 31, 2019, June 30, 2019, September 30, 2019 and December 31, 2019; a (b) deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; and (c) 136,087 shares of common stock held by the Reporting Person. Read SEC document |
| August 29, 2018 Filed Aug 30, 2018 20:07 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 2,500 | $5.74 | $14,350.00 |
DisclosureSEC source: 0001209191-18-048924 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,187 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.73 to $5.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 11,250 restricted stock units which vest quarterly in equal installments on September 30, 2018 and December 31, 2018; and (c) 124,837 shares of common stock held by the Reporting Person. Read SEC document |
| August 29, 2018 Filed Feb 6, 2019 21:10 UTC Amendment | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 2,500 | $5.74 | $14,350.00 |
DisclosureSEC source: 0001209191-19-007711 · doc4a.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,812 F1 · price: This transaction was executed in multiple trades at prices ranging from $5.73 to $5.75. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 11,250 restricted stock units which vest quarterly in equal installments on September 30, 2018 and December 31, 2018; and (c) 130,462 shares of common stock held by the Reporting Person. F3 · balance_after: This amendment is being filed to correct an administrative error by which 5,625 shares were inadvertently omitted from this amount in the reporting person's Form 4 filed on August 30, 2018 and subsequently omitted from the Form 4 filed on January 3, 2019. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 01:50 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | PurchaseCommon Stock | 250 | $76.65 | $19,162.50 |
DisclosureSEC source: 0001179110-18-010976 · edgar.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Pres., Spacelabs Healthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,064 Read SEC document |
| July 05, 2018 Filed Jul 7, 2018 00:24 UTC | OSI SYSTEMS INC OSIS · Entity 4160 | GrantCommon Stock | 3,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-009550 · edgar.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Pres., Spacelabs Healthcare 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,814 Read SEC document |
| May 24, 2018 Filed May 29, 2018 20:33 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 18,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-033839 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,312 F1 · shares: Represents a deferred stock award of 18,100 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 24, 2019. F2 · balance_after: Includes (a) a deferred stock award of 18,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 17, 2018, immediately prior to the commencement of such meeting, and (ii) May 17, 2019; (b) a deferred stock award of 16,875 restricted stock units which vest quarterly in equal installments on June 30, 2018, September 30, 2018 and December 31, 2018; and (c) 122,337 shares of common stock held by the Reporting Person. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 13:36 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001614 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,212 F1 · shares: Represents a deferred stock award of 22,500 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2018. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 22,500 restricted stock units which vest quarterly in equal installments on March 31, 2018, June 30, 2018, September 30, 2018 and December 31, 2018; (b) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; and (c) 85,412 shares of common stock held by the Reporting Person. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 20:09 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 6,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043259 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,712 F1 · shares: Represents a deferred stock award of 6,500 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017. This retainer award was granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on a committee of the Issuer's Board of Directors that the reporting person was appointed to following the 2017 annual meeting of stockholders. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the applicable retainer all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of April, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 14,800 restricted stock units which vest quarterly in equal installments on September 30, 2017 and December 31, 2017; and (c) 70,612 shares of common stock held by the Reporting Person. Read SEC document |
| June 08, 2017 Filed Jun 9, 2017 20:04 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | PurchaseCommon Stock | 7,712 | $2.55 | $19,665.60 |
DisclosureSEC source: 0001209191-17-038851 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,212 F1 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 12,450 restricted stock units which vest quarterly in equal installments on June 30, 2017, September 30, 2017 and December 31, 2017; and (c) 66,462 shares of common stock held by the Reporting Person. Read SEC document |
| May 25, 2017 Filed May 31, 2017 00:40 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 31,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-036302 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,500 F1 · shares: Represents a deferred stock award of 31,300 restricted stock units which fully vest on the earlier to occur of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018. F2 · balance_after: Includes (a) a deferred stock award of 31,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 18, 2017, immediately prior to the commencement of such meeting, and (ii) May 18, 2018; (b) a deferred stock award of 12,450 restricted stock units which vest quarterly in equal installments on June 30, 2017, September 30, 2017 and December 31, 2017; and (c) 58,750 shares of common stock held by the Reporting Person. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 21:43 UTC | HARVARD BIOSCIENCE INC HBIO · Entity 7369 | GrantCommon Stock | 16,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-001019 · doc4.xml · nonDerivative · entry 1 Green James W · CIK 0001400121 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,200 F1 · shares: Represents a deferred stock award of 16,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017, and are subject to continued service as a non-employee director on the applicable vesting dates. These retainer awards are granted in lieu and satisfaction of the annual cash retainer compensation to be earned by the director for his service on the Issuer's Board of Directors and its Committees during 2017. The number of shares of common stock subject to such retainer award is equal to the amount of cash that would have been received had the retainers all been paid in cash, divided by the average daily closing market price of the Issuer's common stock for the month of November, rounded to the nearest 100 shares. F2 · balance_after: Includes (a) a deferred stock award of 16,600 restricted stock units which vest quarterly in equal installments on March 31, 2017, June 30, 2017, September 30, 2017 and December 31, 2017; (b) a deferred stock award of 25,300 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after July 1, 2016, immediately prior to the commencement of such meeting, and (ii) July 1, 2017; and (c) 29,300 shares of common stock held by the Reporting Person. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 20:24 UTC | ANALOGIC CORP ALOG · Entity 165469 | Disposition to issuerRestricted Stock Units · Derivative | 13,390 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032672 · doc4.xml · derivative · entry 7 Green James W · CIK 0001400121 · Director · President/CEO/Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217 Underlying: Common Stock · 13,390 shares Expires not disclosed F4 · derivative.exercise_price: Represents forfeiture of performance based RSU's granted on 9/15/16 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2019. F4 · price: Represents forfeiture of performance based RSU's granted on 9/15/16 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2019. F3 · derivative.exercise_date: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 F3 · derivative.expiration_date: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 20:24 UTC | ANALOGIC CORP ALOG · Entity 165469 | Disposition to issuerRestricted Stock Units · Derivative | 7,628 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032672 · doc4.xml · derivative · entry 6 Green James W · CIK 0001400121 · Director · President/CEO/Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,449 Underlying: Common Stock · 7,628 shares Expires not disclosed F3 · derivative.exercise_price: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 F3 · price: Represents forfeiture of performance based RSUs granted on 9/10/15 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2018 F2 · derivative.exercise_date: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. F2 · derivative.expiration_date: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 20:24 UTC | ANALOGIC CORP ALOG · Entity 165469 | Disposition to issuerRestricted Stock Units · Derivative | 3,749 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032672 · doc4.xml · derivative · entry 5 Green James W · CIK 0001400121 · Director · President/CEO/Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,246 Underlying: Common Stock · 3,749 shares Expires not disclosed F2 · derivative.exercise_price: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. F2 · price: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. F2 · derivative.exercise_date: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. F2 · derivative.expiration_date: Represents forfeiture of performance based RSUs granted on 9/08/14 in connection with the grantee's resignation as an officer of the Company effective October 31, 2016. The remaining RSUs will vest based on the Company's performance as determined following the performance period, which ends on July 31, 2017. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 20:24 UTC | ANALOGIC CORP ALOG · Entity 165469 | Disposition to issuerRestricted Stock Units · Derivative | 4,939 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032672 · doc4.xml · derivative · entry 4 Green James W · CIK 0001400121 · Director · President/CEO/Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,939 shares Expires not disclosed F1 · derivative.exercise_price: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · price: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · derivative.exercise_date: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · derivative.expiration_date: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 20:24 UTC | ANALOGIC CORP ALOG · Entity 165469 | Exercise / conversionRestricted Stock Units · Derivative | 2,469 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-16-032672 · doc4.xml · derivative · entry 3 Green James W · CIK 0001400121 · Director · President/CEO/Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,949 Underlying: Common Stock · 2,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · price: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · derivative.exercise_date: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. F1 · derivative.expiration_date: Represents the accelerated vesting of one-third of the 7,408 time-based restricted stock units ("RSUs") granted on 9/10/15 in connection with the grantee's resignation as an officer of Analogic Corporation (the "Company") effective October 31, 2016, which converted into common stock of the Company on a 1:1 basis. The remainder of the RSU grant was cancelled effective October 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.